Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma-Reference-Cited by-同舟云学术

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Published:2010-09 Issue:7315 Volume:467 Page:596-599
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Bollag Gideon,Hirth Peter,Tsai James,Zhang Jiazhong,Ibrahim Prabha N.,Cho Hanna,Spevak Wayne,Zhang Chao,Zhang Ying,Habets Gaston,Burton Elizabeth A.,Wong Bernice,Tsang Garson,West Brian L.,Powell Ben,Shellooe Rafe,Marimuthu Adhirai,Nguyen Hoa,Zhang Kam Y. J.,Artis Dean R.,Schlessinger Joseph,Su Fei,Higgins Brian,Iyer Raman,D’Andrea Kurt,Koehler Astrid,Stumm Michael,Lin Paul S.,Lee Richard J.,Grippo Joseph,Puzanov Igor,Kim Kevin B.,Ribas Antoni,McArthur Grant A.,Sosman Jeffrey A.,Chapman Paul B.,Flaherty Keith T.,Xu Xiaowei,Nathanson Katherine L.,Nolop Keith

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature09454.pdf

Reference28 articles.

1. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007)

2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002)

3. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006)

4. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518–5527 (2010)

5. Flaherty, K. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)

Cited by 1568 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity;European Journal of Medicinal Chemistry;2024-11

2. A NRAS mRNA G-quadruplex structure-targeting small-molecule ligand reactivating DNA damage response in human cancer cells for combination therapy with clinical PI3K inhibitors;International Journal of Biological Macromolecules;2024-11

3. MEK inhibitors in oncology: a patent review and update (2016 - present);Expert Opinion on Therapeutic Patents;2024-09-14

4. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

5. Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma;Cancer Treatment Reviews;2024-09